CRSP vs BEAM
CRSP and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $5.01B | $2.40B |
| P/B | — | 2.25 |
| P/S | 1427.0x | 17.2x |
| Revenue | — | $156.03M(TTM) |
| Revenue growth (YoY) | -90.6% | 120.0% |
| Net income | — | -$86.52M(TTM) |
| Earnings growth (YoY) | -58.8% | 78.8% |
| EPS, diluted | — | $-0.69(TTM) |
| EBIT margin | -18933.6% | -274.6% |
| ROE | -33.3% | -7.5% |
| ROIC | -32.6% | -40.5% |
| 1y total return | -10.5% | +9.3% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: CRSP vs BEAM
| 지표 | CRSP | BEAM |
|---|---|---|
| 최종 가치 | $9.5K | $12.4K |
| 총수익률 | -4.6% | +23.8% |
| CAGR | -0.7% | +3.3% |
| 변동성 | 61.7% | 79.9% |
| 샤프 | 0.23 | 0.38 |
| 소르티노 | 0.35 | 0.59 |
| 최대 낙폭 | -85.1% | -89.1% |
공통 거래일 1660일 기준, 2020-02-06 → 2026-09-15 · 무위험수익률 4.11% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)